Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CPB1 | P15086 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14193328 | 1.00 | ALDH1A1 (0.52) | ALDH1A1GAACPB1TSHRCA1 | |
| SCHEMBL1718206 | 0.90 | CA1 (0.54) | ALDH1A1GAACPB1TSHRCA1 | |
| SCHEMBL4574080 | 0.84 | CPB1 (0.60) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL4088176 | 0.82 | CPB1 (0.59) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL4088179 | 0.82 | CPB1 (0.59) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL13370746 | 0.82 | CPB1 (0.59) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL4093654 | 0.82 | CPB1 (0.59) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL170233 | 0.82 | ALDH1A1 (0.65) | ALDH1A1GAACPB1TSHRCA1 | |
| SCHEMBL24324120 | 0.81 | CPB1 (0.61) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL8092161 | 0.81 | ALDH1A1 (0.50) | ALDH1A1GAATSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365061-B2 | 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| WO-2006055463-A2 | 2-AMINO-3-FUNCTIONALIZED TETRALIN DERIVATIVES AND RELATED GLYCOGEN PHOSPHORYLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060111413-A1 | Antidiabetic agents, anticancer, non-cardiac ischemia, infection, hypertension, obesity and dislipidemia; 3-(5-chloroindole-2-carbonylamino)-2-hydroxy-1,2,3,4-tetrahydronaphthalene | BRISTOL-MYERS SQUIBB COMPANY | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111413-A1 | Antidiabetic agents, anticancer, non-cardiac ischemia, infection, hypertension, obesity and dislipidemia; 3-(5-chloroindole-2-carbonylamino)-2-hydroxy-1,2,3,4-tetrahydronaphthalene | PYGM, PON1, GYS1 | ALDH1A1 1037/4885GAA 872/4885CPB1 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.